|
Craniofacial Dysostosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Crouzon syndrome is the result of a gain-of-function point mutation in FGFR2.
|
31463736 |
2019 |
|
Carcinoma
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Testing for FGFR2 amplification might be warranted when searching for actionable genomic alterations in sebaceous carcinomas in the mediastinum and in other locations.
|
31401665 |
2020 |
|
Sebaceous Adenocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma.
|
31401665 |
2020 |
|
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The FGFR2-inhibitory activity of PRO-007 was confirmed in genetically modified GC cell lines.
|
31396354 |
2019 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The FGFR2-inhibitory activity of PRO-007 was confirmed in genetically modified GC cell lines.
|
31396354 |
2019 |
|
Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor 2 (FGFR2) might have an important role in the pathogenesis and biology of cholangiocarcinoma (CCA).
|
31351075 |
2019 |
|
Congenital contractural arachnodactyly
|
0.030 |
Biomarker
|
disease |
BEFREE |
The in vitro data correlated with the expression of FGFRs in human CCA specimens by immunohistochemistry (FGFR1, 30% positive; and FGFR2, 65% positive) and the CCA cell lines assayed by Western blot analysis.
|
31351075 |
2019 |
|
Apert syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Chemotherapy and radiotherapy do not increase levels of spontaneous FGFR2 mutations in sperm but, unexpectedly, highly-sterilizing treatments dramatically reduce the levels of the disease-associated c.755C > G (Apert syndrome) mutation in sperm.
|
31348830 |
2019 |
|
Mesonephroma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Herein, we report a case of well-differentiated mesonephric adenocarcinoma with an FGFR2 mutation not previously reported in the literature.
|
31335448 |
2019 |
|
Cervical Mesonephric Adenocarcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Cervical Mesonephric Adenocarcinoma With Novel FGFR2 Mutation.
|
31335448 |
2019 |
|
Craniofacial dysostosis type 1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Crouzon syndrome is usually caused by pathogenic variants in the fibroblast growth factor receptor 2 (FGFR2) gene.
|
31318164 |
2019 |
|
Craniofacial Dysostosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Crouzon syndrome is usually caused by pathogenic variants in the fibroblast growth factor receptor 2 (FGFR2) gene.
|
31318164 |
2019 |
|
Degenerative polyarthritis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Extremely severe scoliosis, heterotopic ossification, and osteoarthritis in a three-generation family with Crouzon syndrome carrying a mutant c.799T>C FGFR2.
|
31318164 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, FGFR2 silencing using small interfering RNA imitated the tumor suppressive effects of miR-889 overexpression in cervical cancer cells, which was successfully reversed by plasmid-facilitated FGFR2 overexpression.
|
31316631 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MicroRNA-889-3p targets FGFR2 to inhibit cervical cancer cell viability and invasion.
|
31316631 |
2019 |
|
Malignant tumor of cervix
|
0.030 |
Biomarker
|
disease |
BEFREE |
These observations demonstrated that miR-889 may serve tumor suppressive roles in cervical cancer by directly targeting FGFR2, which indicated that this miRNA may be a promising therapeutic target for patients with cervical cancer.
|
31316631 |
2019 |
|
Cervix carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These observations demonstrated that miR-889 may serve tumor suppressive roles in cervical cancer by directly targeting FGFR2, which indicated that this miRNA may be a promising therapeutic target for patients with cervical cancer.
|
31316631 |
2019 |
|
cervical cancer
|
0.030 |
Biomarker
|
disease |
BEFREE |
These observations demonstrated that miR-889 may serve tumor suppressive roles in cervical cancer by directly targeting FGFR2, which indicated that this miRNA may be a promising therapeutic target for patients with cervical cancer.
|
31316631 |
2019 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
The serum expression levels of miR-628, prostate-specific antigen, fibroblast growth factor 1, and FGFR2 were examined in patients with PCa.
|
31316598 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The serum expression levels of miR-628, prostate-specific antigen, fibroblast growth factor 1, and FGFR2 were examined in patients with PCa.
|
31316598 |
2019 |
|
Soft tissue chondroma
|
0.010 |
Biomarker
|
disease |
BEFREE |
RNA sequencing identified a fusion involving FN1 and fibroblast growth factor receptor 2 (FGFR2) in the case of soft tissue chondroma and FISH confirmed recurrent involvement of both FGFR1 and FGFR2.
|
31273315 |
2019 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor-2 (<i>FGFR2</i>) gene is amplified in up to 15% of patients with gastric cancer (GC).
|
31258762 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor-2 (<i>FGFR2</i>) gene is amplified in up to 15% of patients with gastric cancer (GC).
|
31258762 |
2019 |
|
Congenital small ears
|
0.410 |
GeneticVariation
|
disease |
BEFREE |
Fetal microtia and FGFR2 polymorphism.
|
31258676 |
2019 |
|
Congenital Microtia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The rs3135718-G gene in FGFR2 has a certain association with the incidence of congenital microtia with high prevalence and risk.
|
31258676 |
2019 |